Gubra raised earnings guidance for full-year 2023. Organic revenue growth to be 25-28% compared to previous guidance of 16-21%. EBIT-margin excl.
special items to be 26-28% compared to previous guidance of Around 25%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
326 DKK | -0.61% | +2.19% | +160.80% |
05-07 | Gubra A/S Announces Management Changes | CI |
04-17 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
Gubra raised earnings guidance for full-year 2023. Organic revenue growth to be 25-28% compared to previous guidance of 16-21%. EBIT-margin excl.
special items to be 26-28% compared to previous guidance of Around 25%.
1st Jan change | Capi. | |
---|---|---|
+160.80% | 775M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |